EQS-Adhoc

H&R GmbH & Co. KGaA: Preliminary Results for FY 2023 - Seite 2

Relief effects due to lower raw material costs

For the year as a whole, operating cash flow recovered strongly to EUR 119.1 million (2022: EUR 38.0 million) despite a lower consolidated result. A lower net working capital requirement relieved the free cash flow, which improved from EUR -34.5 million to EUR 62.8 million. Total assets amounted to EUR 904.2 million at the end of the 2023 financial year (31/12/2022: EUR 962.1 million). Equity amounted to EUR 457.6 million as at the balance sheet date (31/12/2022: EUR 471.2 million). The equity ratio was 50.6% (31.12.2022: 49.0%). 

For a complete presentation of the business development including segment reporting and the annual financial statements, H&R KGaA refers to the publication of the Annual Report 2023 on March 28, 2024.

Contact:
H&R GmbH & Co. KGaA, Head of Investor Relations / Communication, Ties Kaiser
Neuenkirchener Straße 8, 48499 Salzbergen
Phone.: [phone], Fax: [phone]
Mail: [e-mail]
www.hur.com

H&R GmbH & Co. KGaA:

Listed in the Prime Standard of the Frankfurt Stock Exchange, H&R GmbH & Co. KGaA is a specialty chemicals company active in the development and manufacture of chemical-pharmaceutical specialty products based on fossil, bio-based, synthesized and recycled hydrocarbons and in the production of precision plastic parts.

Forward-looking statements and forecasts:

This insider information pursuant to Article 17 of the Market Abuse Regulation [MAR] contains forward-looking statements. The statements are based on the current estimates and forecasts by the Management Team and the information available to it at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this insider information pursuant to Article 17 of the MAR.